Uncovering metabolic vulnerabilities of central nervous system leukemia using metabolic profiling of cerebrospinal fluid and an in vivo CRISPR screen

利用脑脊液代谢分析和体内 CRISPR 筛选揭示中枢神经系统白血病的代谢脆弱性

• 批准号: 457141
• 负责人: Wong Alan Y
• 金额: $ 7.65万
• 依托单位: Harvard Medical School (Boston, Massachusetts)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-10-01 至 2024-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=457141&lang=en
• 关键词: Cerebrospinal Fluid; Chemotherapy Toxicity; Combination Therapy; In Vivo Crispr Screen; Mass Spectrometry; Metabolism; Patient Samples; Pediatric Leukemia; Survivors' Quality Of Life; Xenograft Mouse Model

Leukemia is the most common childhood cancer and the second greatest cause of pediatric cancer mortality in Canada. Chemotherapy directed to the central nervous system (CNS) is a critical part of treatment because leukemia that spreads there is often fata

白血病是加拿大最常见的儿童癌症，也是导致儿童癌症死亡的第二大原因。针对中枢神经系统(CNS)的化疗是治疗的关键部分，因为在那里扩散的白血病通常是失败的